Question 1

What is Idorsia?

Accepted Answer

Idorsia is a Company.

Question 2

How often does Idorsia appear in global news?

Accepted Answer

Tracked across 3 news events drawn from 19 articles.

Question 3

When was Idorsia first tracked by Ergen?

Accepted Answer

First tracked on Apr 30, 2026.

Question 4

When was Idorsia last mentioned in news?

Accepted Answer

Last active on Jul 27, 2026.

Question 5

What is Idorsia's current news sentiment?

Accepted Answer

Aggregate sentiment score: 52 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Idorsia in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 3 events.

Question 7

What is the most recent event involving Idorsia?

Accepted Answer

Idorsia C. difficile vaccine positive results (May 31, 2026, 6 articles).

Question 8

How did the "Idorsia C. difficile vaccine positive results" event impact Idorsia?

Accepted Answer

Idorsia announced positive clinical results for its C. difficile vaccine, IDOR-1134-2831, which validates its synthetic glycan vaccine technology and could lead to significant future revenue and market position.

Question 9

How did the "Idorsia partners Jamjoom Pharma for QUVIVIQ" event impact Idorsia?

Accepted Answer

Idorsia enters exclusive partnership to distribute QUVIVIQ in Saudi Arabia and Levant, receiving upfront payment and royalties; stock rose 8.19%.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.